Etzer Darout
Stock Analyst at BMO Capital
(2.18)
# 2,912
Out of 4,944 analysts
111
Total ratings
36.9%
Success rate
-1.43%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SRRK Scholar Rock Holding | Maintains: Outperform | $57 → $45 | $32.18 | +39.84% | 4 | Aug 7, 2025 | |
| TERN Terns Pharmaceuticals | Maintains: Outperform | $26 → $15 | $6.53 | +129.71% | 5 | May 13, 2025 | |
| IVA Inventiva | Maintains: Buy | $12 → $9 | $4.02 | +123.88% | 3 | Apr 4, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $82 → $20 | $6.88 | +190.70% | 4 | Mar 12, 2025 | |
| PTGX Protagonist Therapeutics | Reiterates: Outperform | $62 → $72 | $56.19 | +28.14% | 2 | Mar 11, 2025 | |
| BNTX BioNTech SE | Maintains: Outperform | $130 → $143 | $111.04 | +28.78% | 4 | Mar 11, 2025 | |
| MRUS Merus | Maintains: Outperform | $91 → $96 | $66.17 | +45.09% | 6 | Feb 28, 2025 | |
| QTTB Q32 Bio | Downgrades: Market Perform | $22 → $3 | $1.75 | +71.43% | 3 | Feb 11, 2025 | |
| IGMS IGM Biosciences | Downgrades: Market Perform | $21 → $2 | $1.27 | +57.48% | 2 | Jan 10, 2025 | |
| EXEL Exelixis | Downgrades: Market Perform | $36 → $40 | $38.37 | +4.25% | 3 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $21.93 | +128.00% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $35 | $10.27 | +240.80% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $55 | $40.39 | +36.17% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $63 | $2.85 | +2,110.53% | 1 | Dec 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $27 | $1.30 | +1,976.92% | 7 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $132 → $134 | $77.60 | +72.68% | 6 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $32 → $34 | $7.35 | +362.59% | 5 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 → $48 | $22.53 | +113.05% | 3 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $118 → $120 | $121.07 | -0.88% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $26 → $25 | $8.52 | +193.43% | 6 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $5 | $1.62 | +209.60% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $2.33 | +758.37% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $1.09 | +453.00% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $3.25 → $3.59 | $1.73 | +107.51% | 10 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $77.91 | +5.25% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $5.05 | +276.24% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $431.12 | -60.57% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $54 | $47.73 | +13.14% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $64.97 | -41.51% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $1.70 | +2,958.82% | 1 | Mar 28, 2018 |
Scholar Rock Holding
Aug 7, 2025
Maintains: Outperform
Price Target: $57 → $45
Current: $32.18
Upside: +39.84%
Terns Pharmaceuticals
May 13, 2025
Maintains: Outperform
Price Target: $26 → $15
Current: $6.53
Upside: +129.71%
Inventiva
Apr 4, 2025
Maintains: Buy
Price Target: $12 → $9
Current: $4.02
Upside: +123.88%
Arvinas
Mar 12, 2025
Maintains: Outperform
Price Target: $82 → $20
Current: $6.88
Upside: +190.70%
Protagonist Therapeutics
Mar 11, 2025
Reiterates: Outperform
Price Target: $62 → $72
Current: $56.19
Upside: +28.14%
BioNTech SE
Mar 11, 2025
Maintains: Outperform
Price Target: $130 → $143
Current: $111.04
Upside: +28.78%
Merus
Feb 28, 2025
Maintains: Outperform
Price Target: $91 → $96
Current: $66.17
Upside: +45.09%
Q32 Bio
Feb 11, 2025
Downgrades: Market Perform
Price Target: $22 → $3
Current: $1.75
Upside: +71.43%
IGM Biosciences
Jan 10, 2025
Downgrades: Market Perform
Price Target: $21 → $2
Current: $1.27
Upside: +57.48%
Exelixis
Dec 20, 2024
Downgrades: Market Perform
Price Target: $36 → $40
Current: $38.37
Upside: +4.25%
Dec 6, 2024
Initiates: Outperform
Price Target: $50
Current: $21.93
Upside: +128.00%
Dec 6, 2024
Initiates: Outperform
Price Target: $35
Current: $10.27
Upside: +240.80%
Dec 6, 2024
Initiates: Market Perform
Price Target: $55
Current: $40.39
Upside: +36.17%
Dec 6, 2024
Initiates: Outperform
Price Target: $63
Current: $2.85
Upside: +2,110.53%
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $1.30
Upside: +1,976.92%
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $77.60
Upside: +72.68%
Nov 8, 2024
Reiterates: Outperform
Price Target: $32 → $34
Current: $7.35
Upside: +362.59%
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $22.53
Upside: +113.05%
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $121.07
Upside: -0.88%
Aug 13, 2024
Maintains: Outperform
Price Target: $26 → $25
Current: $8.52
Upside: +193.43%
Aug 7, 2024
Maintains: Market Perform
Price Target: $8 → $5
Current: $1.62
Upside: +209.60%
Aug 6, 2024
Reiterates: Outperform
Price Target: $20
Current: $2.33
Upside: +758.37%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $1.09
Upside: +453.00%
May 9, 2024
Maintains: Market Perform
Price Target: $3.25 → $3.59
Current: $1.73
Upside: +107.51%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $77.91
Upside: +5.25%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $5.05
Upside: +276.24%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $431.12
Upside: -60.57%
Feb 26, 2021
Initiates: Buy
Price Target: $54
Current: $47.73
Upside: +13.14%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $64.97
Upside: -41.51%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $1.70
Upside: +2,958.82%